The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.
Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...
Together, Risklick and Citeline deliver an integrated, intelligent protocol development experience that combines smart ...
TORONTO, April 3, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...
The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...
A new £50 million initiative aims to cut the length of time novel medicines spend in clinical trials, enabling patients to benefit from new treatments much sooner.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback